The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy

Yangzom D. Bhutia, Ellappan Babu, Puttur D Prasad, Vadivel Ganapathy

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Tumor cells have an increased demand for glucose and amino acids to support their rapid growth, and also exhibit alterations in biochemical pathways that metabolize these nutrients. Transport across the plasma membrane is essential to feed glucose and amino acids into these tumor cell-selective metabolic pathways. Transfer of amino acids across biological membranes occurs via a multitude of transporters; tumor cells must upregulate one or more of these transporters to satisfy their increased demand for amino acids. Among the amino acid transporters, SLC6A14 stands out with specific functional features uniquely suited for the biological needs of the tumor cells. This transporter is indeed upregulated in tumors of epithelial origin, including colon cancer, cervical cancer, breast cancer, and pancreatic cancer. Since normal cells express this transporter only at low levels, blockade of this transporter should lead to amino acid starvation selectively in tumor cells, thus having little effect on normal cells. This offers a novel, yet logical, strategy for the treatment of cancers that are associated with upregulation of SLC6A14. In addition, a variety of amino acid-based prodrugs are recognized as substrates by SLC6A14, thus raising the possibility that anticancer drugs can be delivered into tumor cells selectively via this transporter in the form of amino acid prodrugs. This strategy allows exposure of SLC6A14-positive tumor cells to chemotherapy with minimal off-target effects. In conclusion, the amino acid transporter SLC6A14 holds great potential not only as a direct drug target for cancer therapy but also for tumor cell-selective delivery of anticancer drugs.

Original languageEnglish (US)
Pages (from-to)293-303
Number of pages11
JournalAsian Journal of Pharmaceutical Sciences
Volume9
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Amino Acid Transport Systems
Drug Therapy
Amino Acids
Neoplasms
Prodrugs
Up-Regulation
Pharmaceutical Preparations
Breast Neoplasms
Glucose
Second Primary Neoplasms
Starvation
Metabolic Networks and Pathways
Pancreatic Neoplasms
Uterine Cervical Neoplasms
Colonic Neoplasms
Cell Membrane

Keywords

  • Amino acid transporters
  • Cancer therapy
  • Essential amino acids
  • Glutamine addiction
  • Prodrugs
  • SLC6A14

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy. / Bhutia, Yangzom D.; Babu, Ellappan; Prasad, Puttur D; Ganapathy, Vadivel.

In: Asian Journal of Pharmaceutical Sciences, Vol. 9, No. 6, 01.12.2014, p. 293-303.

Research output: Contribution to journalReview article

Bhutia, Yangzom D. ; Babu, Ellappan ; Prasad, Puttur D ; Ganapathy, Vadivel. / The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy. In: Asian Journal of Pharmaceutical Sciences. 2014 ; Vol. 9, No. 6. pp. 293-303.
@article{81902fce96e34bf5998d21f9ce44b188,
title = "The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy",
abstract = "Tumor cells have an increased demand for glucose and amino acids to support their rapid growth, and also exhibit alterations in biochemical pathways that metabolize these nutrients. Transport across the plasma membrane is essential to feed glucose and amino acids into these tumor cell-selective metabolic pathways. Transfer of amino acids across biological membranes occurs via a multitude of transporters; tumor cells must upregulate one or more of these transporters to satisfy their increased demand for amino acids. Among the amino acid transporters, SLC6A14 stands out with specific functional features uniquely suited for the biological needs of the tumor cells. This transporter is indeed upregulated in tumors of epithelial origin, including colon cancer, cervical cancer, breast cancer, and pancreatic cancer. Since normal cells express this transporter only at low levels, blockade of this transporter should lead to amino acid starvation selectively in tumor cells, thus having little effect on normal cells. This offers a novel, yet logical, strategy for the treatment of cancers that are associated with upregulation of SLC6A14. In addition, a variety of amino acid-based prodrugs are recognized as substrates by SLC6A14, thus raising the possibility that anticancer drugs can be delivered into tumor cells selectively via this transporter in the form of amino acid prodrugs. This strategy allows exposure of SLC6A14-positive tumor cells to chemotherapy with minimal off-target effects. In conclusion, the amino acid transporter SLC6A14 holds great potential not only as a direct drug target for cancer therapy but also for tumor cell-selective delivery of anticancer drugs.",
keywords = "Amino acid transporters, Cancer therapy, Essential amino acids, Glutamine addiction, Prodrugs, SLC6A14",
author = "Bhutia, {Yangzom D.} and Ellappan Babu and Prasad, {Puttur D} and Vadivel Ganapathy",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.ajps.2014.04.004",
language = "English (US)",
volume = "9",
pages = "293--303",
journal = "Asian Journal of Pharmaceutical Sciences",
issn = "1818-0876",
publisher = "Hong Kong Asiamed Publishing House",
number = "6",

}

TY - JOUR

T1 - The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy

AU - Bhutia, Yangzom D.

AU - Babu, Ellappan

AU - Prasad, Puttur D

AU - Ganapathy, Vadivel

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Tumor cells have an increased demand for glucose and amino acids to support their rapid growth, and also exhibit alterations in biochemical pathways that metabolize these nutrients. Transport across the plasma membrane is essential to feed glucose and amino acids into these tumor cell-selective metabolic pathways. Transfer of amino acids across biological membranes occurs via a multitude of transporters; tumor cells must upregulate one or more of these transporters to satisfy their increased demand for amino acids. Among the amino acid transporters, SLC6A14 stands out with specific functional features uniquely suited for the biological needs of the tumor cells. This transporter is indeed upregulated in tumors of epithelial origin, including colon cancer, cervical cancer, breast cancer, and pancreatic cancer. Since normal cells express this transporter only at low levels, blockade of this transporter should lead to amino acid starvation selectively in tumor cells, thus having little effect on normal cells. This offers a novel, yet logical, strategy for the treatment of cancers that are associated with upregulation of SLC6A14. In addition, a variety of amino acid-based prodrugs are recognized as substrates by SLC6A14, thus raising the possibility that anticancer drugs can be delivered into tumor cells selectively via this transporter in the form of amino acid prodrugs. This strategy allows exposure of SLC6A14-positive tumor cells to chemotherapy with minimal off-target effects. In conclusion, the amino acid transporter SLC6A14 holds great potential not only as a direct drug target for cancer therapy but also for tumor cell-selective delivery of anticancer drugs.

AB - Tumor cells have an increased demand for glucose and amino acids to support their rapid growth, and also exhibit alterations in biochemical pathways that metabolize these nutrients. Transport across the plasma membrane is essential to feed glucose and amino acids into these tumor cell-selective metabolic pathways. Transfer of amino acids across biological membranes occurs via a multitude of transporters; tumor cells must upregulate one or more of these transporters to satisfy their increased demand for amino acids. Among the amino acid transporters, SLC6A14 stands out with specific functional features uniquely suited for the biological needs of the tumor cells. This transporter is indeed upregulated in tumors of epithelial origin, including colon cancer, cervical cancer, breast cancer, and pancreatic cancer. Since normal cells express this transporter only at low levels, blockade of this transporter should lead to amino acid starvation selectively in tumor cells, thus having little effect on normal cells. This offers a novel, yet logical, strategy for the treatment of cancers that are associated with upregulation of SLC6A14. In addition, a variety of amino acid-based prodrugs are recognized as substrates by SLC6A14, thus raising the possibility that anticancer drugs can be delivered into tumor cells selectively via this transporter in the form of amino acid prodrugs. This strategy allows exposure of SLC6A14-positive tumor cells to chemotherapy with minimal off-target effects. In conclusion, the amino acid transporter SLC6A14 holds great potential not only as a direct drug target for cancer therapy but also for tumor cell-selective delivery of anticancer drugs.

KW - Amino acid transporters

KW - Cancer therapy

KW - Essential amino acids

KW - Glutamine addiction

KW - Prodrugs

KW - SLC6A14

UR - http://www.scopus.com/inward/record.url?scp=84919644742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919644742&partnerID=8YFLogxK

U2 - 10.1016/j.ajps.2014.04.004

DO - 10.1016/j.ajps.2014.04.004

M3 - Review article

VL - 9

SP - 293

EP - 303

JO - Asian Journal of Pharmaceutical Sciences

JF - Asian Journal of Pharmaceutical Sciences

SN - 1818-0876

IS - 6

ER -